On October 5, 2023 Agenus Inc. (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, reported that the Company will host a corporate event to discuss advancements in its botensilimab/balstilimab (BOT/BAL) program at the upcoming European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Conference on Sunday, October 22, 2023 (Press release, Agenus, OCT 5, 2023, View Source [SID1234635692]). Agenus will provide updates from the ongoing BOT/BAL clinical program, including in neoadjuvant colorectal cancer and pancreatic cancer. A live webcast of the event will be available.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Speakers include:
Alexander Eggermont, M.D., Ph.D., University Medical Center, Utrecht, Princess Maxima Center for Pediatric Oncology, Comprehensive Cancer Center
Marwan Fakih, M.D., City of Hope
Manuel Hidalgo, M.D., Ph.D., Weill Cornell Medicine
Pashtoon Kasi, M.D., M.S., Weill Cornell Medicine
Breelyn Wilky, M.D., University of Colorado Medicine
Steven O’Day, M.D., Chief Medical Officer, Agenus
Todd Yancey, M.D., Senior Advisor, Agenus
Event Details
Date: Sunday, October 22, 2023
Time: 19:00 – 21:00 CEST (1:00 p.m. – 3:00 p.m. EDT)
To register for the webcast, please click here.